BR112015023439A2 - combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki - Google Patents
combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tkiInfo
- Publication number
- BR112015023439A2 BR112015023439A2 BR112015023439A BR112015023439A BR112015023439A2 BR 112015023439 A2 BR112015023439 A2 BR 112015023439A2 BR 112015023439 A BR112015023439 A BR 112015023439A BR 112015023439 A BR112015023439 A BR 112015023439A BR 112015023439 A2 BR112015023439 A2 BR 112015023439A2
- Authority
- BR
- Brazil
- Prior art keywords
- egfr
- combination
- tki
- ovens
- micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo “combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki” a divulgação fornece métodos e composições para tratar células de câncer, incluindo células de câncer em um paciente no qual dois ou mais agentes terapêuticos são usados, um sendo um agente egfr-tki e o outro sendo um microrna.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787558P | 2013-03-15 | 2013-03-15 | |
US201461927543P | 2014-01-15 | 2014-01-15 | |
PCT/US2014/028006 WO2014143855A2 (en) | 2013-03-15 | 2014-03-14 | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023439A2 true BR112015023439A2 (pt) | 2017-07-18 |
Family
ID=50678292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023439A BR112015023439A2 (pt) | 2013-03-15 | 2014-03-14 | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki |
Country Status (11)
Country | Link |
---|---|
US (2) | US20140309278A1 (pt) |
EP (1) | EP2968567A2 (pt) |
JP (1) | JP2016519076A (pt) |
KR (1) | KR20150131312A (pt) |
CN (1) | CN105263523A (pt) |
AU (1) | AU2014228166A1 (pt) |
BR (1) | BR112015023439A2 (pt) |
CA (1) | CA2903882A1 (pt) |
EA (1) | EA201591543A1 (pt) |
MX (1) | MX2015013177A (pt) |
WO (1) | WO2014143855A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2302055T3 (da) | 2004-11-12 | 2014-10-13 | Asuragen Inc | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler |
WO2012041959A1 (en) | 2010-09-30 | 2012-04-05 | University Of Zurich | Treatment of b-cell lymphoma with microrna |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
CN106255756A (zh) * | 2014-02-28 | 2016-12-21 | 米尔纳疗法公司 | 肝癌的索拉非尼‑微rna联合疗法 |
WO2016161196A1 (en) * | 2015-04-03 | 2016-10-06 | Mirna Therapeutics, Inc. | Microrna-34 immunotherapy |
US20180185446A1 (en) * | 2015-06-15 | 2018-07-05 | Vital Therapies, Inc. | Composition and method for inducing anti-apoptosis, survival or proliferation of a cell |
KR101876724B1 (ko) * | 2016-05-09 | 2018-07-13 | 주식회사 싸이토젠 | 폐암 환자의 혈중 순환 종양세포를 활용한 egfr-tki 내성 환자의 맞춤형 항암제 선별시스템 및 방법 |
CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
JP7226763B2 (ja) * | 2017-08-17 | 2023-02-21 | 国立大学法人山口大学 | 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法 |
WO2019103578A1 (ko) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
US11492671B2 (en) | 2018-04-11 | 2022-11-08 | Istituti Fisioterapici Ospitalieri | MiRNAs for treatment and in vitro diagnosis of drug resistant tumors |
JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロrnaの非正規標的を抑制するrna干渉誘導核酸およびその用途 |
WO2020219668A1 (en) * | 2019-04-24 | 2020-10-29 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treating ras-mutant cancers |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
US7858117B2 (en) | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
DK2302055T3 (da) | 2004-11-12 | 2014-10-13 | Asuragen Inc | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler |
CA2611944A1 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
AU2008261951A1 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | miR-34 regulated genes and pathways as targets for therapeutic intervention |
CN102112110A (zh) | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
WO2011059752A1 (en) * | 2009-10-28 | 2011-05-19 | Board Of Regents Of The University Of Texas System | Methods and compositions for anti-egfr treatment |
CA2781571A1 (en) * | 2009-11-24 | 2011-06-03 | The University Of Western Australia | Modulation of epidermal growth factor receptor ligands |
SG10201600836PA (en) * | 2011-02-03 | 2016-03-30 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
JP6271432B2 (ja) * | 2011-09-30 | 2018-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗ErbB3抗体およびその使用 |
CA2858382A1 (en) * | 2011-12-10 | 2013-06-13 | Ohio State Innovation Foundation | Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods |
-
2014
- 2014-03-14 CA CA2903882A patent/CA2903882A1/en not_active Abandoned
- 2014-03-14 JP JP2016502684A patent/JP2016519076A/ja active Pending
- 2014-03-14 KR KR1020157029657A patent/KR20150131312A/ko not_active Application Discontinuation
- 2014-03-14 EA EA201591543A patent/EA201591543A1/ru unknown
- 2014-03-14 AU AU2014228166A patent/AU2014228166A1/en not_active Abandoned
- 2014-03-14 MX MX2015013177A patent/MX2015013177A/es unknown
- 2014-03-14 BR BR112015023439A patent/BR112015023439A2/pt not_active IP Right Cessation
- 2014-03-14 CN CN201480026816.XA patent/CN105263523A/zh active Pending
- 2014-03-14 EP EP14722032.1A patent/EP2968567A2/en not_active Withdrawn
- 2014-03-14 US US14/212,105 patent/US20140309278A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/028006 patent/WO2014143855A2/en active Application Filing
-
2015
- 2015-06-10 US US14/736,177 patent/US20150272981A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016519076A (ja) | 2016-06-30 |
US20140309278A1 (en) | 2014-10-16 |
MX2015013177A (es) | 2016-10-03 |
AU2014228166A1 (en) | 2015-09-24 |
CA2903882A1 (en) | 2014-09-18 |
EA201591543A1 (ru) | 2016-09-30 |
WO2014143855A3 (en) | 2014-12-04 |
CN105263523A (zh) | 2016-01-20 |
KR20150131312A (ko) | 2015-11-24 |
EP2968567A2 (en) | 2016-01-20 |
WO2014143855A2 (en) | 2014-09-18 |
US20150272981A1 (en) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12021550052A1 (en) | Methods of treating and preventing graft versus host disease | |
CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
MX2017013983A (es) | Uso de agentes activos durante tratamientos quimicos. | |
BR112018007447A2 (pt) | terapia de combinação para tratamento de malignidades | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112015013123A2 (pt) | inibidores de beta-lactamase | |
BR112015020584A2 (pt) | métodos para o tratamento de artrite psoriática usando apremilast | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
BR112018007656A2 (pt) | terapia de combinação para tratamento de doenças malignas | |
AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. | |
BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |